重组人生长激素对提高多囊卵巢综合征患者妊娠率的临床研究  

Clinical research of rhGH on pregnancy rate of polycysticovary syndrome

作　　者：何艳舫[1] 刘萍[1] 韩素新[1] 左振伟[1] 

机构地区：[1]河北联合大学附属医院妇产科,唐山063000

出　　处：《中国综合临床》2013年第8期790-792,共3页Clinical Medicine of China

基　　金：唐山市科学技术研究与发展计划项目（12140209A-54）

摘　　要：目的探讨重组人生长激素（rhGH）对提高多囊卵巢综合征（PCOS）患者妊娠率的作用。方法选择2012年2—8月来我院门诊就诊的82例PCOS患者为研究对象，所有研究对象经纠正异常激素水平后随机分为两组，rhGH组（41例）在促排卵周期加用rhGH，并指导受孕。对照组（41例）直接促排卵治疗并指导受孕。对两组的排卵率、妊娠率及子宫内膜评分进行比较。结果rhGH组的排卵率为90．2％（37／41），对照组为68．2％（28／41），差异有统计学意义（#=3．459，P=0．036）。rhGH组的临床妊娠率为32．7％（12／37），对照组为25．0％（7／28），差异有统计学意义（χ2=4．319，P=0．032）。rhGH组子宫内膜评分为（14．96±2．18）分，对照组为（12．77±2．60）分，组间比较差异有统计学意义（t=-3．356，P=0．032）。结论促排卵周期规范地给予rhGH可促进PCOS患者排卵，改善影响妊娠的不良因素，提高妊娠率。Objective To investigate the effect of recombinant human growth hormone （rhGH） action on pregnancy rate of polyeystic ovarian syndrome（PCOS）. Methods The PCOS who were client in our hospital in February-August,2012 were investigated. The rhGH group （41 cases） were that all patients took rhGH at the same time ovulation. The control group （41 eases） were no medication group. The two groups had sex action after ovulation. Ovulation rate, pregnancy rate and endometrial score of the two groups were compared. Results Ovulation rate of rhGH group was 90. 2% （37/41） ,the control group was 68. 2% （28/41） ,the difference was statistically significant （ χ2 = 3.459, P = 0. 036 ）. Clinical pregnancy rate of RhGH group was 32. 7 % （ 12/37 ）, the control group was 25.0% （ 7/28 ）. The difference was statistics significance （ χ2 = 4. 319, P = 0. 032 ）. Endometrial score of rhGH group was （ 14. 96 ＋ 2. 18 ）, the control group was （ 12.77 ± 2.60 ） points, the difference between groups was statistically significant （ t = - 3. 356, P = 0. 032 ）. Conclusion Giving rhGH ovulation cycle specification can promote ovulation PCOS patients and improve the adverse factors affecting oreanancv, imnrovin~ the nre,,nancv rate.

关 键 词：多囊卵巢综合征 重组人生长激素 妊娠 

分 类 号：R711[医药卫生—妇产科学]